Page last updated: 2024-11-03

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid and Graft vs Host Disease

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid has been researched along with Graft vs Host Disease in 1 studies

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert
5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.

Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.

Research Excerpts

ExcerptRelevanceReference
" Therefore, the present study aimed to trial a modified injection regime using more frequent dosing of BBG to improve outcomes in this model of GVHD."1.62P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model. ( Adhikary, SR; Casolin, S; Cuthbertson, P; Geraghty, NJ; Sluyter, R; Watson, D, 2021)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Cuthbertson, P1
Geraghty, NJ1
Adhikary, SR1
Casolin, S1
Watson, D1
Sluyter, R1

Other Studies

1 other study available for pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid and Graft vs Host Disease

ArticleYear
P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model.
    Clinical science (London, England : 1979), 2021, 02-12, Volume: 135, Issue:3

    Topics: Adult; Animals; B-Lymphocytes; Disease Models, Animal; Female; Graft vs Host Disease; Hematopoietic

2021